Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies

NCT05608876 is registered in ClinicalTrials.gov with QBiotics Group Limited as lead sponsor.

NCT NCT05608876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05608876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies
Lead sponsor
QBiotics Group Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 3, 2022
Completion date
August 31, 2026
Enrollment
15 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer